Pharma calls for action as report shows huge local variations in use of NICE-approved drugs
A report showing huge variations in access to some new medicines in England, has prompted the UK's pharma trade body to call for the National Health Service (NHS) to take fresh action to solve the problem.
Slow or patchy take-up of medicines newly recommended by NICE for NHS use has long been a concern of the industry, and the report published on Tuesday shows that in some cases variation in use can be marked.
The report was produced by a working group from the Department of Health, its Health and Social Care Information Centre, NICE and a working group of the Association of the British Pharmaceutical Industry (ABPI).
The ABPI pointed out that the report, called "Use of NICE-appraised medicines in the NHS in England", showed there was a 29-fold difference in usage of certain new anticoagulants.
In total the report assessed access to 54 NICE-recommended drugs relating to 47 technology appraisals.